GeneCentric Therapeutics Acquires Select ImmunoGenomics
(WorldNews Business)

DURHAM, N.C.--(BUSINESS WIRE)--Aug 15, 2019-- GeneCentric Therapeutics, Inc. today announced that it has acquired Select ImmunoGenomics, LLC, a Chapel Hill, NC-based provider of advanced immunogenomic, data analysis and biomarker development services to support the development of immuno-oncology drugs. The acquisition provides the combined company with a comprehensive, integrated set of RNA-based solutions to enhance drug development by identifying the right patients for oncology drugs, improving response rates and durability, and ultimately patient outcomes. Financial terms were...